Meiji Seika Pharma Co., Ltd. has been decided to construct a new manufacturing facility at Adcock Ingram Ltd. (Headquarters: Bengaluru India, Managing Director: G.V. Ramireddy) in Bengaluru, India, to enhance its production capacity of the contract manufacturing organization (CMO) business.
Adcock Ingram Ltd., established in 2007, is a joint venture between Adcock Ingram Holdings Ltd., in South Africa, and Medreich Ltd. (Headquarters: Bengaluru India, Managing Director: Pankaj Garg), a wholly-owned subsidiary of Meiji Seika Pharma Co., Ltd. Adcock Ingram Ltd. manufactures pharmaceutical products, by contract manufacturing, and distributes for the South African, European and Oceanian markets. By adding the new manufacturing facility, it can manufacture pharmaceutical products not only for the Adcock Ingram Group, but also for other clients. The new manufacturing facility is built at a subsidiary of Adcock Ingram Ltd. and is scheduled to start operation in March 2023.
The Meiji Group's Pharmaceutical Segment, in its "2023 Medium-Term Business Plan", has set an agenda to "Expand CMO/CDMO business" in its business strategies. We will continue to optimize our production bases in Japan and overseas to strengthen our production system and establish a system for the stable supply of highly reliable pharmaceuticals and contribute to improving access to pharmaceuticals for people over the world.
Overview of the new manufacturing facility:
(1) Location
41/42, Bommasandra Industrial Area, Anekal Taluk, Bangalore 560 099, India
(2) Site area
Approx. 8,000㎡
(3) Total floor area
Approx. 7,878㎡
(4) Construction costs
Approx. USD 20.1 million
(5) Production capacity
(annual)
Tablets: 750 million tablets
Sachets: 75 million packages
Bottles: 4 million bottles
(6) Start of operations
March 2023
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!